Bayburina, GA,
Nurgaleeva, EA,
Samigullina, AF,
Farshatova, ER,
Ganeev, TI,
Agletdinov, EF,
Tarasova, TV (2021) of the treatment group (n=35) under ether
anesthesia, we were stopping stopping systemic circulation for five
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) and children. The present trial was a
safety and
dose-finding study for weekly MOD-4023 in GHD children.
Design
Onorato, EM,
Alamanni, F,
Muratori, M,
Smolka, G,
Wojakowski, W,
Pysz, P,
Zorinas, A,
Zakarkaite, D,
Eltchaninoff, H,
Litzer, PY,
Godart, F,
Calvert, P,
Christou, C,
Mussayev, A,
Missiroli, B,
Buzaev, I,
Curello, S,
Tesorio, T,
Bartorelli, AL (2022) leaks (PVLs) were enrolled at 21 sites in 10 countries.
Safety data were available for 137 patients, who
Wei, XM,
Zhang, F,
Qiu, YK,
Shen, H,
Ilyasova, T,
Liu, L. (2022) resonance imaging (MRI) before surgery. Before
anesthesia, the patient underwent lumbar drainage
Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) the efficacy and
safety of once-weekly somatrogon with once-daily somatropin in prepubertal children with
GHD
permanent neonatal diabetes to address the key questions relating to long-term efficacy and
safetyChatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) the pharmacokinetics, pharmacodynamics,
safety, and efficacy of weekly TransCon GH to that of daily GH in prepubertal